Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.50 |
| ▸ | MAP3K8 | P41279 | 14/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193466 | 0.82 | EGFR (0.52) | EGFRERBB2MAP3K8 | |
| SCHEMBL13480787 | 0.80 | EGFR (0.50) | EGFRERBB2MAP3K8CYP3A4MAPKAPK2 | |
| SCHEMBL13480784 | 0.78 | EGFR (0.51) | EGFRERBB2MAP3K8 | |
| SCHEMBL13480789 | 0.78 | EGFR (0.54) | EGFRERBB2MAP3K8 | |
| SCHEMBL13480746 | 0.77 | EGFR (0.66) | EGFRERBB2MAP3K8 | |
| SCHEMBL13480765 | 0.77 | EGFR (0.54) | EGFRERBB2MAP3K8 | |
| SCHEMBL3192981 | 0.74 | EGFR (0.67) | EGFRMAP3K8 | |
| SCHEMBL13480792 | 0.74 | MAP3K8 (0.47) | EGFRERBB2MAP3K8 | |
| SCHEMBL13480749 | 0.73 | EGFR (0.54) | EGFRERBB2MAP3K8 | |
| SCHEMBL5608261 | 0.73 | EGFR (0.71) | EGFRERBB2MAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659284-B2 | Inhibitors of ATP-protein kinase; 7-(3-chloro-4-fluoro-phenylamino)-2-(4-pyrrolidin-1-ylmethyl-phenylamino)-thiazolo[4,5-b]pyridine-6-carbonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-09 | — | — | US | disclosed |
| EP-1789055-A2 | THIAZOLOPYRIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006031929-A2 | THIAZOLOPYRIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058341-A1 | Thiazolopyridine kinase inhibitors | PRKACA, PRKCE, MAP3K9 | EGFR 991/4885ERBB2 199/4885MAP3K8 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.